Table 2.
Treatment effect (adjusted mean difference) for spirometry variables at 24, 48 and 72 weeks
| Outcome | Adjusted mean difference (95% CI) | |||
|---|---|---|---|---|
| 24 weeks (n = 312) | 48 weeks (n = 308) | 72 weeks (n = 248) | Overall effect | |
| FEV1 | -0.12 [-0.31, 0.07] | 0.04 [-0.01, 0.09] | 0.05 [-0.07, 0.16] | 0.004 [-0.08, 0.09] |
| FEV1 z-score | -0.02 [-0.05, 0.02] | 0.02 [-0.04, 0.09] | 0.03 [-0.05, 0.10] | 0.004 [-0.08, 0.09] |
| FVC | -0.19 [-0.51, 0.12] | 0.04 [-0.02, 0.09] | 0.06 [-0.07, 0.19] | 0.03 [-0.02, 0.09] |
| FVC z-score | -0.03 [-0.09, 0.03] | 0.04 [-0.05, 0.13] | 0.04 [-0.06, 0.13] | 0.02 [-0.07, 0.12] |
| FEV1/FVC | 0.02 [-0.03, 0.08] | 0.01 [-0.01, 0.02] | -0.01 [-0.03, 0.02] | 0.005 [0.01, 0.02] |
| FEV1/FVC z-score | 0.02 [-0.04, 0.08] | -0.01 [-0.11, 0.09] | 0.03 [-0.07, 0.14] | -0.01 [-0.12, 0.09] |
The models shows adjusted mean differences between the intervention and placebo arms with negative values indicating lower values in the intervention arm as compared to the placebo. The xtgee models were adjusted for sex, age, site and natural log HIV viral load